Provided by Tiger Trade Technology Pte. Ltd.

INmune Bio Inc

1.51
-0.0600-3.82%
Volume:215.54K
Turnover:336.45K
Market Cap:40.14M
PE:-0.72
High:1.67
Open:1.64
Low:1.49
Close:1.57
52wk High:11.64
52wk Low:1.38
Shares:26.59M
Float Shares:20.18M
Volume Ratio:2.20
T/O Rate:1.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1078
EPS(LYR):-2.1100
ROE:-155.77%
ROA:-50.59%
PB:1.58
PE(LYR):-0.72

Loading ...

INmune Bio announces FDA alignment on phase 2b/3 registration pathway

TIPRANKS
·
Yesterday

INmune Bio Advances XPro1595 to Phase 2b/3 Trial in Early Alzheimer’s Disease

Reuters
·
Yesterday

INmune Bio Inc - FDA Indicates No Objection to Integrated Phase 2B/3 Design

THOMSON REUTERS
·
Yesterday

BRIEF-Inmune Bio Advances Cordstrom™ Towards Uk Marketing Authorization In Rdeb

Reuters
·
Feb 10

INmune Bio Inc: Submitted Pre-Submission Package for Cordstrom With UK's Mhra

THOMSON REUTERS
·
Feb 10

INmune Bio Advances Cordstrom™ Towards UK Marketing Authorization in Rdeb

THOMSON REUTERS
·
Feb 10

INmune Bio Submits CORDStrom Pre-Submission Package to UK MHRA for RDEB Review

Reuters
·
Feb 10

INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives

GlobeNewswire
·
Jan 27

INmune Bio Inc: Files for Common Stock Offering of $65 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Dec 20, 2025

INmune Bio Inc - Company Terminates Sales Agreement Effective December 19, 2025 - SEC Filing

THOMSON REUTERS
·
Dec 11, 2025

INmune Bio Inc - on Dec 5, Enters Amendment No. 5 to Rights Agreement - SEC Filing

THOMSON REUTERS
·
Dec 09, 2025

INmune Bio Reports Phase 2 Trial Data Showing XPro1595 Slows Neurodegeneration in Early Alzheimer’s Disease

Reuters
·
Dec 06, 2025

INmune Bio Highlights CORDStrom Platform’s Promise in Stromal Cell Therapy Research

Reuters
·
Dec 05, 2025

INmune Bio Inc. Updates Executive Compensation Agreements

Reuters
·
Dec 04, 2025

INmune Bio Reports Positive Phase 2 Imaging Data for XPro1595 in Early Alzheimer's Disease

Reuters
·
Dec 01, 2025

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

GlobeNewswire
·
Nov 18, 2025

INmune Bio Q3 net loss narrows to $6.5 mln, names new CEO

Reuters
·
Oct 31, 2025

INmune Bio Q3 Adj. EPS $(0.24) Beats $(0.33) Estimate

Benzinga
·
Oct 31, 2025

INmune Bio Q3 Basic EPS USD -0.24

THOMSON REUTERS
·
Oct 31, 2025

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

GlobeNewswire
·
Oct 31, 2025